Relay doubles the bar, outpacing Novartis with a 60% response in rare disease

Relay Therapeutics reported a 60% volumetric response rate for zovegalisib in the Phase 2 ReInspire trial, with a later data cutoff implying a 65% ORR (13/20) after one additional unconfirmed responder. The results compare favorably with Leerink’s 20%–25% success bar and Novartis’ 11% ORR for Vijoice, supporting discussion of an accelerated approval path. Tolerability also looked manageable, with no dose discontinuations and only 2 patients (9%) experiencing grade 3+ TRAEs, and the stock rose 9% intraday.

Analysis

RLAY now has a credible shot at converting a development asset into a near-term commercial catalyst, and the market is likely underappreciating how rare that is in rare-disease biotech: a differentiated efficacy signal in a small, biomarker-defined population can compress the usual multi-year de-risking cycle into a regulatory event over the next 6-12 months. The key second-order effect is not just product value, but platform validation: a mutant-selective inhibitor that can outperform the incumbent standard materially strengthens the company’s broader PI3Kα franchise and raises the odds that the market begins capitalizing the oncology pipeline with a lower discount rate.

The competitive readthrough is more negative for NVS than the headline implies. A failed incumbent in this niche creates a much higher burden of proof for any follow-on therapy and makes physician switching easier if access is granted; that matters because specialty centers and payors tend to anchor on the best available volumetric response, not legacy brand status. If Relay sustains the signal, the bigger loser may be not just Vijoice economics but the broader notion that this category should be priced like a modestly differentiated rare-disease asset rather than a platform with expansion optionality.

The main risk is that the current re-rate can outrun the evidence base. Accelerated approval still needs a clean, reproducible endpoint package, and the 12-week readout is enough to excite traders but not enough to eliminate durability, tolerability, and payer-friction risk over the next 3-9 months. The stock is likely to remain highly sensitive to any hint that response depth plateaus, adverse events scale with dose, or the FDA pushes for a more conservative confirmatory framework.

Consensus may be missing that the best trade is not necessarily a blind long into the data, but a structured expression around regulatory optionality. If the market starts valuing VM as the lead asset, RLAY can de-correlate from the broader biotech tape; however, if investors extrapolate one small, enriched cohort into a full franchise rerate, the move could become crowded quickly. That sets up a favorable asymmetry in owning upside through defined-risk structures while respecting binary event risk on the path to approval.

Key Decisions for Investors

• Long RLAY on pullbacks over the next 1-2 weeks; target a 15-25% re-rate if the market begins capitalizing accelerated-approval odds, with a stop if the FDA narrative shifts to a slower confirmatory path.
• Buy RLAY call spreads 3-6 months out to express regulatory optionality with capped downside; prefer strikes that monetize a move toward a platform valuation rather than just a one-day data pop.
• Pair trade: long RLAY / short NVS over the next 1-3 months to isolate mutant-selective PI3Kα differentiation versus legacy inhibitor skepticism; the spread should widen if payor and clinician adoption concerns intensify for the incumbent.
• For risk-controlled traders, sell post-event volatility only after the first regulatory update if the stock overshoots on headline enthusiasm; the better short entry is a failed confirmatory or FDA-process delay, not the initial enthusiasm phase.
• Watch for expansion-cohort dosing updates and any pediatric data; if tolerability remains clean at higher chronic exposure, that is the next catalyst to extend the move beyond the initial approval trade.